Table 1 Characteristics of the study sample.

From: Association of cortical microstructure with amyloid-β and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults

Characteristic

All participants

(n = 196)

Aβ−

(n = 147)

Aβ+

(n = 49)

P value

No. (% of sample)

 Female, no. (%)

114 (58.2%)

86 (58.5%)

28 (57.1%)

0.87

 White/non-hispanic, no. (%)

148 (75.5%)

105 (71.4%)

43 (87.8%)

0.02

 APOE-ε4+

53 (27.0%)

23 (15.6%)

30 (61.2%)

<0.001

 CDR = 0.5

9 (4.6%)

8 (5.4%)

1 (2.0%)

0.32

Mean (SD)

 Age, years

72.5 (9.4)

70.9 (9.6)

77.3 (7.2)

<0.001

 Years of education

16.2 (2.9)

16.2 (3.0)

16.0 (2.8)

0.63

 MMSE

29.1 (1.1)

29.1 (1.1)

29.2 (1.1)

0.80

 Logical memory, delayed recall

15.7 (3.9)

15.7 (3.9)

15.7 (3.9)

>0.99

 PACC5

0.19 (0.75)

0.22 (0.75)

0.09 (0.74)

0.30

 PIB-FLR DVR

1.17 (0.19)

1.08 (0.04)

1.45 (0.19)

<0.001

 entFTP PVC SUVr

1.36 (0.29)

1.29 (0.23)

1.56 (0.34)

<0.001

 i-tFTP PVC SUVr

1.44 (0.18)

1.40 (0.15)

1.56 (0.21)

<0.001

 No. follow-up MRI scans

 Prospective MRI follow-up, years

 Subsample n/total n (%)

1.47 (0.52)

3.11 (1.52)

118/196 (60.2%)

1.44 (0.50)

3.01 (1.50)

79/147 (53.7%)

1.51 (0.56)

3.31 (1.55)

39/49 (79.6%)

0.49

0.31

 No. follow-up cognitive assessments

 Prospective cognitive follow-up, years

 Subsample n/total n (%)

3.56 (1.80)

3.72 (1.96)

186/196 (94.9%)

3.40 (1.81)

3.50 (1.92)

138/147 (93.9%)

4.04 (1.71)

4.34 (1.95)

48/49 (98.0%)

0.03

0.01

 Prospective clinical follow-up, years

 Subsample n/total n (%)

 Progressors to MCI, n/total (%)

 Time-to-progression in those who progressed, years

3.2 (1.7)

163/196 (83.2%)

11/163 (6.7%)

3.3 (1.5)

3.1 (1.7)

116/147 (78.9%)

1/116 (0.86%)

4.5 (−)

3.4 (1.6)

47/49 (95.9%)

10/47 (21.3%)

3.2 (1.5)

0.30

 Prospective CDR follow-up, years

 Subsample n/total n (%)

 Progressors to CDR = 0.5, n/total (%)

 Time-to-CDR = 0.5 in those who progressed, years

3.3 (1.7)

165/187 (88.2%)

15/165 (9.1%)

2.7 (1.7)

3.3 (1.6)

119/139 (85.6%)

3/119 (2.5%)

3.4 (0.9)

3.3 (1.8)

46/48 (95.8%)

12/46 (26.1%)

2.5 (1.9)

>0.99

  1. Participant information is presented for the full sample and at two levels of Aβ burden. Statistical differences between the Aβ+ and the Aβ− groups were computed using two-sample t tests or chi-square t tests, as appropriate. APOE-ε4 data were missing for 12 participants.
  2. APOE apolipoprotein, CDR Clinical Dementia Rating, DVR distribution volume ratio, entFTP entorhinal 18F-flortaucipir, i-tFTP inferior-temporal 18F-flortaucipir, FTP 18F-flortaucipir, PIB-FLR frontal, lateral temporo-parietal and retrosplenial composite PIB-PET, MCI mild cognitive impairment, MMSE mini-mental state examination, PACC5 Preclinical Alzheimer Cognitive Composite-5, PVC partial volume corrected, SD standard deviation, SUVr standardized uptake value ratio.
Back to article page